Previous close | 0.5990 |
Open | 0.6300 |
Bid | 0.5900 x 900 |
Ask | 0.6100 x 1300 |
Day's range | 0.5990 - 0.6300 |
52-week range | 0.5600 - 1.7500 |
Volume | |
Avg. volume | 44,700 |
Market cap | 31.966M |
Beta (5Y monthly) | 1.16 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.7200 |
Earnings date | 14 Nov 2023 - 20 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.00 |
NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 being held October 11-15, 2023 in Boston, Massachusetts. The details of NuCana’s presentations at the meeting are as follows: Abstract title: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with adva
We can readily understand why investors are attracted to unprofitable companies. For example, although...